与切除胆道癌症的观察结果相比,辅助剂S-1 (JCOG1202,ASCOT):一个多中心的,开放的,随机的,受控的,第三期试验

Kohei Nakachi1, Masafumi Ikeda2, Masaru Konishi3

  • 1Department of Medical Oncology, Tochigi Cancer Center, Utsunomiya, Japan; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Lancet (London, England)
|January 21, 2023
PubMed
概括

在切除的胆道癌症患者中,辅助S-1化疗显著改善了整体存活率. 这一发现表明S-1可能成为治疗这种癌症的新标准.